<DOC>
	<DOCNO>NCT01766037</DOCNO>
	<brief_summary>This research study perform find new device , AspireAssist Aspiration Therapy System , help people obesity lose weight without cause many side effect .</brief_summary>
	<brief_title>Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study</brief_title>
	<detailed_description>The Aspiration process work `` correct '' meal portion eat remove food leave stomach 20 minute meal , reduces number calorie absorb body . This do tube place abdomen stomach small valve attach surface skin . An aspiration system attach valve major meal day allow remove portion meal . During study also provide Lifestyle therapy include behavioral therapy , diet physical activity education . This Lifestyle therapy also provide participant receive AspireAssist two group compare benefit aspiration weight loss determine .</detailed_description>
	<criteria>1 . Measured BMI 35.055.0 kg/m2 time screen . 2 . 21 65 year age ( inclusive ) time screen . 3 . Failed attempt duration equal 3months weight loss alternative approach ( e.g . supervise unsupervised diet , exercise , behavioral modification program ) . 4 . Stable weight ( &lt; 3 % change selfreported weight ) previous 3 month time screen ) . 5 . Women childbearing potential must agree use least one form birth control ( prescription hormonal contraceptive , diaphragm , IUD , condom without spermicide , voluntary abstinence ) time study enrollment study exit . 6 . Willing able provide inform consent English comply protocol . 1 . Previous abdominal surgery significantly increase medical risk gastrostomy tube placement 2 . Esophageal stricture , pseudoobstruction , severe gastroparesis gastric outlet obstruction , inflammatory bowel disease 3 . History refractory gastric ulcer 4 . Ulcers , bleed lesion , tumor discover endoscopic examination . 5 . History radiation therapy chest abdomen 6 . Uncontrolled hypertension ( blood pressure &gt; 160/100 ) . 7 . Diabetes treat insulin sulfonylurea medication 8 . Any change diabetes medication previous 3 month 9 . Hemoglobin A1C &gt; 9.5 % 10 . History evidence serious pulmonary cardiovascular disease , include acute coronary syndrome , heart failure require medication , NYHA ( New York Heart Association ) class III IV heart failure ( define ) : Class III : patient marked limitation activity comfortable rest Class IV : patient complete rest , confine bed chair discomfort physical activity 11 . Coagulation disorder ( platelet &lt; 100,000 , PT &gt; 2 second control INR &gt; 1.5 ) 12 . Anemia ( Hemoglobin &lt; 11.0 g/dL woman &lt; 12.5 g/dL men ) 13 . Liver enzyme ( ALT AST ) ≥3.0 time upper limit normal 14 . Thyroid Stimulating Hormone ( TSH ) &gt; 1.5 x upper limit normal screening . 15 . Osteoporosis ( DEXA TScore ≤ 2.5 standard deviation normal peak value ) . 16 . History fragility fracture ( fracture result fall stand height less , present absence obvious trauma ) 17 . Pregnant lactate 18 . Diagnosed Bulimia diagnose Binge Eating Disorder ( use DSM IV criterion ) 19 . Night Eating Syndrome ( diagnose EDE ) 20 . Serum potassium &lt; 3.8 mEq/L 21 . Chronic abdominal pain would potentially complicate management device 22 . Taking GLP1 agonist &lt; 6 month . 23 . Taking prescription overthecounter medication weight loss last 3 month screen , plan participate commercial weight loss program next 24 month . 24 . Taking medication per week cause weight gain ( e.g . atypical antipsychotic , monoamine oxidase inhibitor , lithium , select anticonvulsant , tamoxifen , glucocorticoid ) 25 . Self report history substance abuse last 3 year . 26 . Malignancy last 5 year ( except nonmelanoma skin cancer ) . 27 . Physical mental disability , psychological illness could interfere compliance therapy . 28 . At high risk medical complication endoscopic procedure Aspiration Therapy weight loss program reason , include poor general health severe organ dysfunction , cirrhosis renal dysfunction ( GFR &lt; 60 mL/min/1.73 m2 screening , calculate use Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) equation ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>obesity</keyword>
	<keyword>obese</keyword>
	<keyword>weight loss</keyword>
</DOC>